<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>辉瑞/BioNtech疫苗在第三阶段研究的第一次分析中取得成功</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">辉瑞/BioNtech疫苗在第三阶段研究的第一次分析中取得成功</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-09 21:25:19</div><div class="page_narrow text-break page_content"><p>Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis</p><p>在第一次中期疗效分析中发现，候选疫苗在无SARS-CoV-2感染证据的参与者中预防新冠肺炎的有效性超过90%。</p><p>  Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected</p><p>这项研究招募了43,538名参与者，其中42%具有不同的背景，没有观察到严重的安全问题；安全性和额外的疗效数据仍在继续收集。</p><p> Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November</p><p>美国食品和药物管理局(FDA)计划在达到所需的安全里程碑后不久向美国食品和药物管理局(FDA)提交紧急使用授权(EUA)，目前预计在11月的第三周。</p><p> Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints</p><p>继续进行临床试验，对164例确诊病例进行最终分析，以便收集进一步的数据，并针对其他研究终点确定候选疫苗的表现。</p><p> NEW YORK &amp; MAINZ, GERMANY--(BUSINESS WIRE)--  Pfizer Inc. (NYSE: PFE) and  BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.</p><p>纽约&美因茨，德国--(美国商业新闻网)--辉瑞公司。纽约证券交易所股票代码：PFE和生物技术公司(纳斯达克股票代码：BNTX)今天宣布，基于外部独立数据监测委员会于2020年11月8日进行的第三期临床研究的第一次中期疗效分析，他们针对SARS-CoV-2的信使核糖核酸候选疫苗BNT162b2已经在没有SARS-CoV-2感染证据的参与者中证明了对抗新冠肺炎有效的证据。</p><p>  “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.</p><p>他说：“今天对科学和人类来说是伟大的一天。我们新冠肺炎疫苗三期试验的第一组结果初步证明我们的疫苗能够预防新冠肺炎，“辉瑞董事长兼首席执行官Albert Bourla博士说。他说：“我们在疫苗研发项目中达到这一关键里程碑之际，世界最需要它，感染率创历史新高，医院产能接近过剩，经济正在艰难地重新开放。有了今天的新闻，我们离为世界各地的人们提供帮助结束这场全球健康危机的急需的突破又近了重要的一步。我们期待着在未来几周内分享数千名参与者产生的更多疗效和安全性数据。“在与FDA讨论后，这些公司最近决定放弃32例中期分析，而进行第一次中期分析，至少62例。在这些讨论结束后，可评估的病例数达到94例，公积金管理委员会对所有病例进行了第一次分析。在接种疫苗的个人和接受安慰剂的人之间的病例显示，在第二次接种后7天，疫苗有效率超过90%。这意味着在疫苗接种开始后28天即可获得保护，包括2剂疫苗时间表。随着研究的继续，最终的疫苗效力百分比可能会有所不同。公积金委员会没有报告任何严重的安全问题，并建议这项研究继续按计划收集更多的安全性和有效性数据。这些数据将与世界各地的监管机构进行讨论。</p><p> “I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”</p><p>布拉补充说：“我要感谢成千上万自愿参与临床试验的人，感谢我们在研究地点的学术合作者和研究人员，以及我们在世界各地的同事和合作者，他们正在为这项关键的努力奉献自己的时间。”“如果没有参与其中的每一个人的巨大承诺，我们不可能走到今天这一步。”</p><p> “The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”</p><p>我们的全球第三阶段研究的第一次中期分析提供了证据，证明疫苗可以有效地预防新冠肺炎。这是创新、科学和全球合作努力的胜利。“BioNTech联合创始人兼首席执行官Ugur Sahin教授说。“当我们在10个月前踏上这段旅程时，这就是我们渴望实现的目标。特别是今天，当我们都处在第二波浪潮中，我们中的许多人处于封锁状态时，我们更加认识到，这一里程碑在我们结束这一流行病的道路上以及对我们所有人恢复正常感觉的道路上是多么重要。我们将继续收集更多的数据，因为试验继续登记进行最终分析，计划到那时总共发生164例确诊的新冠肺炎病例。我要感谢为取得这一重要成就作出贡献的每一个人。“</p><p> The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at  https://www.pfizer.com/science/coronavirus.</p><p>BNT162b2的3期临床试验于7月27日开始，到目前为止已经招募了43,538名参与者，其中38,955人已经接种了截至2020年11月8日的第二剂候选疫苗。大约42%的全球参与者和30%的美国参与者具有不同的种族和民族背景。审判仍在继续，预计将持续到最终分析，届时共发生164例确诊的新冠肺炎病例。这项研究还将评估候选疫苗在先前接触过SARS-CoV-2的人中对新冠肺炎的保护作用，以及对严重新冠肺炎病的疫苗预防作用。除了评估第二次接种后7天内确诊的新冠肺炎病例的一级疗效终点外，经美国食品和药物管理局批准，现在还将包括根据第二次接种后14天的确诊病例评估疗效的新的二级终点。两家公司相信，这些次级终点的增加将有助于统一所有新冠肺炎疫苗研究的数据，并允许在这些新型疫苗平台之间进行交叉试验学习和比较。这两家公司已经在https://www.pfizer.com/science/coronavirus.上发布了该研究方案的更新版。</p><p> Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.</p><p>辉瑞和BioNTech正在继续积累安全数据，目前估计第二剂(也是最后一剂)候选疫苗后两个月的安全数据的中位数-FDA在其潜在紧急使用授权指南中指定的安全数据量-将在11月的第三周之前提供。此外，参与者将在第二次接种后再接受两年的长期保护和安全监测。</p><p> Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.</p><p>除了临床试验产生的疗效数据，辉瑞和BioNTech正在努力准备必要的安全性和制造数据，以便提交给FDA，以证明生产的疫苗产品的安全性和质量。</p><p> Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.</p><p>根据目前的预测，我们预计2020年全球疫苗产量将达到5000万剂，2021年将达到13亿剂。</p><p> Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.</p><p>辉瑞和BioNTech计划提交完整的第三阶段试验的数据，供科学同行评议发表。</p><p>  At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world&#39;s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at  www.Pfizer.com. In addition, to learn more, please visit us on  www.Pfizer.com and follow us on Twitter at  @Pfizer and  @Pfizer News,  LinkedIn,  YouTube and like us on Facebook at  Facebook.com/Pfizer.</p><p>在辉瑞，我们应用科学和我们的全球资源为人们带来延长和显著改善他们生活的疗法。我们致力于在发现、开发和生产保健品(包括创新药物和疫苗)方面设定质量、安全和价值的标准。每天，辉瑞的同事们在发达国家和新兴市场工作，以促进健康、预防、治疗和治疗，挑战我们这个时代最令人畏惧的疾病。作为世界首屈一指的创新型生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持并扩大世界各地获得可靠、负担得起的医疗保健的机会。150多年来，我们一直致力于为所有依赖我们的人带来改变。我们经常在我们的网站www.pfizer.com上发布对投资者可能很重要的信息。此外，要了解更多信息，请访问www.pfizer.com，在Twitter上关注我们@Pfizer，在@Pfizer News、LinkedIn、YouTube上关注我们，在Facebook上关注我们(Facebook.com/Pfizer)。</p><p>  The information contained in this release is as of November 9, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p><p>本新闻稿中包含的信息截至2020年11月9日。辉瑞公司不承担因新信息或未来事件或发展而更新本新闻稿中包含的前瞻性陈述的义务。</p><p> This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, anticipated timing of clinical trial readouts and regulatory submissions and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.</p><p>本新闻稿包含有关辉瑞对抗新冠肺炎、BioNTech与辉瑞合作开发潜在的新冠肺炎疫苗、BNT162mRNA疫苗计划以及modRNA候选BNT162b2(包括对现有数据的定性评估、潜在益处、临床试验预期、预期的临床试验读数和监管提交时间以及预期的制造、分销和供应)的前瞻性信息，这些风险和不确定性因素可能会导致实际结果与此类声明所表达或暗示的结果产生巨大差异。除其他事项外，风险和不确定性包括研发中固有的不确定性，包括满足预期临床终点的能力、临床试验的开始和/或完成日期、监管提交日期、监管批准日期和/或启动日期，以及与初步和中期数据(包括作为本新闻稿主题的第三阶段临时数据)相关的风险，包括不利的新的临床前或临床试验数据和对现有临床前或临床试验数据的进一步分析的可能性；临床试验数据受到不同解释和评估的风险，包括在</p><p> A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at  www.sec.gov and  www.pfizer.com.</p><p>有关风险和不确定性的进一步描述，请参阅辉瑞截至2019年12月31日的财年的Form 10-K年度报告及其后续的Form 10-Q报告，包括其中标题为“风险因素”和“前瞻性信息和可能影响未来业绩的因素”的部分，以及其后续的Form 8-K报告，这些报告均已提交给美国证券交易委员会(SEC)，并可在www.sec.gov和www.pfizer.com上查阅。</p><p>  Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit   www.BioNTech.de.</p><p>生物制药新技术公司是下一代免疫疗法公司，致力于开创癌症和其他严重疾病的新疗法。该公司利用广泛的计算发现和治疗药物平台来快速开发新型生物制药。其广泛的肿瘤学候选产品组合包括个性化和现成的基于信使核糖核酸的疗法、创新的嵌合抗原受体T细胞、双特异性检查点免疫调节剂、靶向癌症抗体和小分子。基于其在信使核糖核酸疫苗开发和内部制造能力方面的深厚专业知识，BioNTech及其合作者在其多样化的肿瘤学流水线的同时，正在为一系列传染病开发多种信使核糖核酸疫苗候选疫苗。BioNTech已经与多家全球制药合作伙伴建立了广泛的合作关系，其中包括Genmab、赛诺菲、拜耳动物健康、罗氏集团成员Genentech、Genevant、复星制药和辉瑞。欲了解更多信息，请访问www.BioNTech.de。</p><p>  This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC’s website at  www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p><p>本新闻稿包含符合1995年“私人证券诉讼改革法案”的生物技术公司的“前瞻性声明”。这些前瞻性陈述可能包括但不限于以下陈述：BioNTech对抗新冠肺炎的努力；BioNTech与辉瑞公司合作开发潜在的新冠肺炎疫苗；我们对BNT162b2在我们的2/3期试验中和/或在商业使用中的潜在特征(基于迄今的数据观察)的预期；在我们的2/3期试验中额外读取BNT162b2疗效数据的预期时间；临床数据的性质，这还有待同行审查。向FDA提交生产数据的时间；以及BioNTech供应数量BNT162的能力，以支持临床开发和(如果获得批准)市场需求，包括我们对2020年和2021年的产量估计。本新闻稿中的任何前瞻性陈述都是基于BioNTech公司目前对未来事件的预期和信念，会受到许多风险和不确定性的影响，这些风险和不确定性可能会导致实际结果与这些前瞻性陈述中陈述或暗示的结果大相径庭。这些风险和不确定性包括但不限于：在临床试验中满足预定义终点的能力；为新冠肺炎生产疫苗的竞争；产生可比临床或其他结果的能力，包括我们声明的在其余试验中或在商业化后更大、更多样化的人群中观察到的疫苗有效性、安全性和耐受性的比率；以及其他潜在的困难。有关这些和其他风险和不确定性的讨论，请参阅BioNTech于2020年3月31日提交给证券交易委员会的20-F表格年度报告，该报告可在证券交易委员会网站www.sec.gov上查阅。本新闻稿中的所有信息都是截至发布之日的信息，除非法律要求，否则BioNTech不承担更新这些信息的责任。</p><p>   Pfizer Contacts:  Media Relations Amy Rose +1 (212) 733-7410   [email protected]   Investor Relations Chuck Triano +1 (212) 733-3901   [email protected]    BioNTech Contacts:  Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 or +49 (0)151 1978 1385   [email protected]   Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074   [email protected]</p><p>辉瑞公司联系人：媒体关系部艾米·罗斯(Amy Rose)电话：+1(212)733-7410[电子邮件受保护]投资者关系部查克·特里亚诺(Chuck Triano)电话：+1(212)733-3901[电子邮件受保护]BioNTech联系人：媒体关系部贾斯米娜·阿拉托维奇(Jasmina Alatovic)电话：+49(0)6131 9084 1513或+49(0)151 1978 1385[电子邮件受保护]投资者关系部西尔克·马斯(Sylke Maas)博士电话：+49(0)6131 9084 1074[电子邮件受保护]</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/biontech/">#biontech</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/美国/">#美国</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/linux/">#linux</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/程序/">#程序</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>